FStar.jpg
F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA
August 04, 2021 08:00 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
Sunshine Biopharma Logo
Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement
July 27, 2021 09:00 ET | Sunshine Biopharma Inc.
MONTREAL, July 27, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
FStar.jpg
F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors
July 26, 2021 08:00 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company...
LIXTE.jpg
LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM
July 22, 2021 09:25 ET | Lixte Biotechnology Holdings, Inc.
Altadena, CA, July 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXTE) a clinical-stage drug discovery company developing pharmacologically active drugs for improving...
22157.jpg
Global $3.32 Bn Interventional Oncology Devices Market to 2030: Embolization Devices, Ablation Devices, & Support Devices
July 16, 2021 05:53 ET | Research and Markets
Dublin, July 16, 2021 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's...
Sunshine Biopharma Logo
Sunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer
July 08, 2021 09:00 ET | Sunshine Biopharma Inc.
MONTREAL, July 08, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral...
Rubius_Logo.jpg
Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors
June 23, 2021 16:01 ET | Rubius Therapeutics
CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
Advocates Mobilize To Ask President To Fund Colorectal Cancer Research
June 08, 2021 12:49 ET | Fight Colorectal Cancer
Springfield, Mo., June 08, 2021 (GLOBE NEWSWIRE) -- By 2030, it is estimated that colorectal cancer (CRC) will be the leading cause of cancer deaths for those ages 20-49, according to a recent JAMA...
Rubius_Logo.jpg
Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting
May 19, 2021 17:02 ET | Rubius Therapeutics
CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...
22157.jpg
Global Immuno-Oncology Assays Market (2021 to 2026) - Growing Significance of Companion Diagnostics Presents Opportunities
May 14, 2021 05:23 ET | Research and Markets
Dublin, May 14, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Assays Market by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications...